Advanced Search
WEN Lanying. Anti-tumor Effects of Photodynamic Therapy on Mouse B Cell Lymphoma in vitro and in vivo[J]. Cancer Research on Prevention and Treatment, 2014, 41(08): 861-865. DOI: 10.3971/j.issn.1000-8578.2014.08.001
Citation: WEN Lanying. Anti-tumor Effects of Photodynamic Therapy on Mouse B Cell Lymphoma in vitro and in vivo[J]. Cancer Research on Prevention and Treatment, 2014, 41(08): 861-865. DOI: 10.3971/j.issn.1000-8578.2014.08.001

Anti-tumor Effects of Photodynamic Therapy on Mouse B Cell Lymphoma in vitro and in vivo

More Information
  • Objective To investigate the anti-tumor effects of photodynamic therapy(PDT) using Photodithazine, a chlorin e6 derivatives, as photosensitizer(PS) on mouse B cell lymphoma both in vitro and in vivo. Methods After treated with various concentrations (0.125-1.0 μg/ml) of PS, A20 cells were illuminated with 6.25 J/cm2 of laser [wavelength (662 ± 3) nm]. WST-1 assay was performed to detect the cell proliferation, electron microscopy was used to observe morphological changes, and flow cytometry(FACS) was applied to detect the apoptosis rate and the expression of B cell specific antigen-CD45R. We established lymphoma animal model by subcutaneously injecting A20 cells into Balb/c mice. Tumor growth was recorded after PDT intervening in vivo. The expressions of P53, P21 and Bax in tumor tissue were detected by Western blot. Results After PDT for 24 h, the growth of A20 cells was inhibited in the group with > 0.50 μg/ml of PDT(P<0.05), moreover, there was significant inhibition in the group with 0.25 μg/ml of PDT after 48 h (P<0.01). Apoptotic and necrotic cells were detected under the microscope. We successfully established lymphoma animal model and tumor growth was inhibited by PDT in vivo(P<0.05). P53, P21 and Bax were highly expressed in tumor tissues which accepted PDT in vivo. Conclusion Photodithazine/PDT has anti-tumor effects on A20 lymphoma both in vitro and in vivo.
  • [1]
    Moan J, Peng Q. An outline of the hundred-year history of PDT[J]. Anticancer Res, 2003, 23(5A): 3591-600.
    [2]
    Allison R, Moghissi K, Downie G, et al. Photodynamic therapy (PDT) for lung cancer[J]. Photodiagnosis Photodyn Ther, 20 11,8(3):231-9.
    [3]
    Tran Thi Hai Yen, Ignat’eva EV, Polozkova AP, et al. Qualitative and quantitative analysis of a new lyophilized liposomal formulation of photodithazine[J]. Pharma Chem J, 2010, 44 (6):337-40.
    [4]
    Romanko YS, Tsyb AF, Kaplan MA, et al. Relationship between antitumor efficiency of photodynamic therapy with photoditasine and photoenergy density[J]. Bull Exp Biol Med, 2005,139(4): 46 0-4.
    [5]
    Wen LY, Bae SM, Do JH, et al. The effects of photodynamic therapy with Photodithazine on HPV 16 E6/E7 associated cervical cancer model[J]. J Porphyrins Phthalocyanines, 20 11,15(3):174-80.
    [6]
    Wen LY, Bae SM, Ahn WS. Establishment of leukemia mouse model using mouse-derived A20 leukemic cells, and detection of tumor cells in bone marrow[J]. Lab Anim Res, 2010, 26 (4):415-23.
    [7]
    Wen LY, Bae SM, Chun HJ, et al. Therapeutic effects of systemic photodynamic therapy in a leukemia animal model using A20 cells[J]. Lasers Med Sci, 2012,27(2):445-52.
    [8]
    Heier I, Hofgaard PO, Brandtzaeg P, et al. Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma[J]. Clin Exp Immunol, 2008, 15 2(2):381-7.
    [9]
    Ferrario A, von Tiehl KF, Rucker N, et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma[J]. Cancer Res, 2000, 60(15):4066-9.
    [10]
    Bae BC, Na K. Self-quenching polysaccharide-based nanogels of pullulan/folate-photosensitizer conjugates for photodynamic therapy[J]. Biomaterials, 2010, 31(24):6325-35.
    [11]
    Lim DS, Bae SM, Kwak SY, et al. Adenovirus-mediated p53 treatment enhances photodynamic antitumor response[J]. Hum Gene Ther, 2006, 17(3):347-52.
    [12]
    Chan WH. Photodynamic treatment induces an apoptotic pathway involving calcium, nitric oxide, p53, p21-activated Kinase 2, and c-Jun N-terminal Kinase and inactivates survival signal in human umbilical vein endothelial cells[J]. Int J Mol Sci, 2011, 12 (2):1041-59.
    [13]
    Wei XQ, Ma HQ, Liu AH, et al. Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells[J]. Asian Pac J Cancer Prev, 20 13, 14(5):3023-8.
    [14]
    Ling D, Bae BC, Park W, et al. Photodynamic efficacy of photosensitizers under an attenuated light dose via lipid nanocarrier- mediated nuclear targeting[J]. Biomaterials, 2012, 33 (21):5478-86.
    [15]
    Tran TH, Bae BC, Lee YK, et al. Heparin-folate-retinoic acid bioconjugates for targeted delivery of hydrophobic photosensitizers[J]. Carbohydr Polym, 2013, 92(2):1615-24.
  • Related Articles

    [1]CHENG Jianping, ZHAO Xiaolin, LI Zhen, YANG Mengyuan, CAO Shichang, YU Jiufei. Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 542-546. DOI: 10.3971/j.issn.1000-8578.2020.19.1475
    [2]XU Qi, LIU Bixia, GU Linhui, ZHANG Shuangshuang, ZHOU Weimin, WU Xiaodan, YING Jieer, FENG Jianguo. Effects of Different Doses of Bevacizumab on Irinotecan Distribution in Nude Mice Bearing Human Colon Cancer Cell Xenografts[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 263-266. DOI: 10.3971/j.issn.1000-8578.2016.04.005
    [3]WANG Junbin, WU Qiong, ZOU Weiyan, WANG Zishu, YANG Yan, ZHENG Rongsheng. Therapeutic Effect of Raltitrexed or Fluorouracil plus Irinotecan as Second-line Treatment for Advanced Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1335-1338. DOI: 10.3971/j.issn.1000-8578.2014.12.018
    [4]CUI Yongxia, LUO Zhifen, LU Chuangxin, ZHOU Jianwei, MA Ning, ZHOU Yun. Clinical Observation of Irinotecan Combined with Tegafur or 5-Fluorouracil as Second-Line Chemotherapy for Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 808-810. DOI: 10.3971/j.issn.1000-8578.2014.07.026
    [5]ZHAO Rongrong, WANG Yuanfang, LIU Bo, HAN Shumei, NIU Zuoxing. Clinical Study of Irinotecan Plus Cisplatin for Patients with Carcinoma of Unknown Primary Site[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 984-987. DOI: 10.3971/j.issn.1000-8578.2013.10.017
    [6]Zhang Huiqing, He Bo, Lu San, Wan Yiye. Second-line Chemotherapy with Irinotecan Plus Cisplatin for Patients with Advanced Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(11): 1373-1375. DOI: 10.3971/j.issn.1000-8578.2012.11.023
    [7]LI Rong, LIU Xiu-feng, HE Ze-ming, HUA Hai-qing, WANG Lin, CHEN Ying-xia. Preliminary Clinical Observation on Irinotecan Combined with Continuous Infusion of Tegafur in Treating Patients with Advanced Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(12): 1419-1422. DOI: 10.3971/j.issn.1000-8578.2011.12.020
    [8]LI Min, FANG Ming-zhi, QIAN Yin, HUANG Xin, ZHU Xiang. Cetuximab plus Irinotecan in Treatment of Metastatic Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(08): 938-941. DOI: 10.3971/j.issn.1000-8578.2010.08.021
    [9]XU Hua, LIU An-wen, XIE Chun-ying, WU Jian-bing. Clinical Study of TACE with Irinotecan and Lipiodol Combining with Intravenous Chemotherapy of CF/5-Fu in Treatment of Hepatic Metastasis from Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(08): 696-698. DOI: 10.3971/j.issn.1000-8578.2009.08.019
    [10]HUANG Yong, QIN Shu-kui, QIAN Jun, SHAO Zhi-jian, L IU Xiu-Feng, L IAO Shi-bin, GONG Xin-lei. Clinical Study of Weekly Irinotecan in Patients with Metastatic Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 110-112. DOI: 10.3971/j.issn.1000-8578.1199

Catalog

    Article views (1087) PDF downloads (1050) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return